恶性胸膜间皮瘤研究进展

Progress of malignant pleural mesothelioma

恶性胸膜间皮瘤(MPM)是一种少见的起源于胸膜间皮细胞的原发肿瘤,起病隐匿,侵袭性和恶性程度高,病因尚未明确,接触石棉为首要致病因素。早期症状不明显,缺乏特异性症状,且诊断困难,有赖于取病理组织行免疫组织化学以明确诊断。仅有少数患者可接受根治性手术,目前治疗方式主要为化疗,顺铂联合培美曲塞是最常用的化疗方案。患者预后极差,生存期短,仅用支持治疗的中位生存时间为4~12个月。文章就MPM诊断现状及治疗现状的诊断、治疗及进展作一综述。

Malignant pleural mesothelioma (MPM) is a rare primary tumor originating from pleural mesothelial cells. The disease is insidious and the etiology is not yet clear, but exposure to asbestos is the main pathogenic factors. The early symptoms of MPM are not obvious, and owning to the lack of specific symptoms, it's hard to be diagnosed, so it depends on histopathological immunohistochemistry to confirm the diagnosis. Only a few patients can undergo radical surgery. The current treatment is mainly chemotherapy, and cisplatin combined with pemetrexed is the most commonly used chemotherapy. The prognosis of MPM patient is very poor, and the survival period is short. The median survival time of MPM patients after supportive therapy alone is 4-12 months. This article will summarize the status and research progress of diagnosis and treatment of MPM.